Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling.

Saved in:
Bibliographic Details
Title: Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling.
Authors: Zhu YY; School of Pharmacy, Fudan University, and School of Basic Medical Sciences, Fudan University, Shanghai, 201203, China., Li AQ; School of Pharmacy, Fudan University, and School of Basic Medical Sciences, Fudan University, Shanghai, 201203, China., Yang F; School of Pharmacy, Fudan University, and School of Basic Medical Sciences, Fudan University, Shanghai, 201203, China., Dong YX; School of Pharmacy, Fudan University, and School of Basic Medical Sciences, Fudan University, Shanghai, 201203, China., Huang YS; Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, 563000, China., Meng XJ; Shandong Academy of Pharmaceutical Science, Jinan, 250102, China., Zhang DZ; Shandong Academy of Pharmaceutical Science, Jinan, 250102, China., Li Y; School of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macao SAR, China., Xian YF; School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Zhu D; School of Pharmacy, Fudan University, and School of Basic Medical Sciences, Fudan University, Shanghai, 201203, China. zhudi@fudan.edu.cn.; Key Laboratory of Tumor Immunology and Microenvironmental Regulation, and Department of Oncology, Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. zhudi@fudan.edu.cn.; Fudan University Shanghai Cancer Center, Shanghai, 200032, China. zhudi@fudan.edu.cn., Feng M; School of Pharmacy, Fudan University, and School of Basic Medical Sciences, Fudan University, Shanghai, 201203, China. feng_mei@fudan.edu.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Jun 29. Date of Electronic Publication: 2026 Jun 29.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1745-7254
DOI:10.1038/s41401-026-01845-2